XNAS · Healthcare · Biotechnology
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | FY 2025 | — | -3.56 | — | $1.3M | — | +1.40% | -9.25% | +11.09% |
| 2024-11-22 | Q3 2024 | — | -8.40 | — | $168,000 | — | -0.28% | -2.82% | -5.37% |
| 2024-08-15 |
| Q2 2024 |
| — |
| -4.00 |
| — |
| $284,000 |
| — |
| +2.92% |
| +6.37% |
| -10.88% |
| 2024-07-02 | Q1 2024 | — | -4.00 | — | $0 | — | +4.87% | -2.01% | +39.60% |
| 2024-05-15 | Q4 2023 | — | -8.00 | — | $0 | — | +2.27% | -21.82% | -20.68% |
| 2023-08-11 | Q2 2023 | -0.91 | -1.20 | -31.87% | $0 | ❌ Miss | — | — | -2.23% |
| 2023-05-15 | Q1 2023 | -0.73 | -1.20 | -64.38% | $0 | ❌ Miss | — | — | — |
| 2023-04-17 | Q4 2022 | -0.10 | 0.00 | +100.00% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.